Matrine ameliorates the inflammatory response and lipid metabolism in vascular smooth muscle cells through the NF‑κB pathway

Wang,Guanglei; Ji,Chengyu; Wang,Chunling; Liu,Zhonghui; Qu,Aizhong; Wang,Huaixin

doi:10.3892/etm.2021.10744

Matrine ameliorates the inflammatory response and lipid metabolism in vascular smooth muscle cells through the NF‑κB pathway

Authors:
- Guanglei Wang
- Chengyu Ji
- Chunling Wang
- Zhonghui Liu
- Aizhong Qu
- Huaixin Wang
View Affiliations

Affiliations: Department of Emergency Medicine, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China, Department of Cardiology, Linqu People's Hospital, Weifang, Shandong 262600, P.R. China, Department of Stomatology, Linqu People's Hospital, Weifang, Shandong 262600, P.R. China, Hematology Department, Weifang Yidu Central Hospital, Weifang, Shandong 262500, P.R. China
Published online on: September 16, 2021 https://doi.org/10.3892/etm.2021.10744
Article Number: 1309
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis is a chronic inflammatory disease associated with inflammatory responses and the uncontrolled proliferation and excessive apoptosis of vascular smooth muscle cells. However, the effects of matrine on the inflammatory response, abnormal lipid metabolism and cell proliferation and apoptosis marker proteins in human aortic vascular smooth muscle cells (HAVSMCs) have not been elucidated. Therefore, the present study aimed to investigate the effect of matrine on an in vitro model of atherosclerosis using HAVSMCs. The HAVSMCs were divided into normal, model and matrine groups. The model group was treated with oxidized low‑density lipoprotein (oxLDL), the matrine group was treated with oxLDL and matrine and the normal group was treated with physiological saline. Total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE) levels were measured in the cell supernatant. In addition, the relative mRNA levels of inflammatory factors were quantified using reverse transcription‑quantitative PCR, and the cell proliferation and apoptosis rates were evaluated using Cell Counting Kit‑8 and flow cytometry assays, respectively. The expression levels of proteins associated with proliferation and apoptosis were also determined using western blotting. The levels of TC, FC and CE and the mRNA levels of IL‑1β, IL‑6, and TNF‑α in the matrine group were lower than those in the model group, but higher than those in the normal group. After 48 and 96 h of treatment, the cell proliferation and apoptotic rates were lower in the matrine group compared with the model group. The relative expression levels of Ki‑67, proliferating cell nuclear antigen and Bax were decreased, while that of Bcl‑2 was increased in the matrine group compared with the model group. In addition, the relative protein expression of nuclear factor κB (NF‑κB) in the matrine group was lower than that in the model group, but higher than that in the normal group. In summary, matrine inhibited activation of the NF‑κB pathway and reduced cell proliferation and apoptosis in the oxLDL‑induced atherosclerosis model, and exhibited anti‑inflammatory effects. These results suggest that matrine attenuated abnormal biological reactions in HAVSMCs through the NF‑κB pathway.

View Figures

View References

1	Tabas I, García-Cardeña G and Owens GK: Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 209:13–22. 2015.PubMed/NCBI View Article : Google Scholar
2	Gisterå A and Hansson GK: The immunology of atherosclerosis. Nat Rev Nephrol. 13:368–380. 2017.PubMed/NCBI View Article : Google Scholar
3	Feinberg MW and Moore KJ: MicroRNA regulation of atherosclerosis. Circ Res. 118:703–720. 2016.PubMed/NCBI View Article : Google Scholar
4	Bäck M and Hansson GK: Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 12:199–211. 2015.PubMed/NCBI View Article : Google Scholar
5	Libby P and Everett BM: Novel antiatherosclerotic therapies. Arterioscler Thromb Vasc Biol. 39:538–545. 2019.PubMed/NCBI View Article : Google Scholar
6	Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han X, Tang D and Chen R: Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 8(80)2018.PubMed/NCBI View Article : Google Scholar
7	Zhang MJ and Huang J: Recent research progress of anti-tumor mechnism matrine. Zhongguo Zhong Yao Za Zhi. 29:115–118. 2004.PubMed/NCBI(In Chinese).
8	Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and Su C: Anti-tumor activities of matrine and oxymatrine: Literature review. Tumour Biol. 35:5111–5119. 2014.PubMed/NCBI View Article : Google Scholar
9	Suo Z, Liu Y, Ferreri M, Zhang T, Liu Z, Mu X and Han B: Impact of matrine on inflammation related factors in rat intestinal microvascular endothelial cells. J Ethnopharmacol. 125:404–409. 2009.PubMed/NCBI View Article : Google Scholar
10	Yu HB, Zhang HF, Li DY, Zhang X, Xue HZ and Zhao SH: Matrine inhibits matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. J Asian Nat Prod Res. 13:242–250. 2011.PubMed/NCBI View Article : Google Scholar
11	Liu XY, Fang H, Yang ZG, Wang XY, Ruan LM, Fang DR, Ding YG, Wang YN, Zhang Y, Jiang XL and Chen HC: Matrine inhibits invasiveness and metastasis of human malignant melanoma cell line A375 in vitro. Int J Dermatol. 47:448–456. 2008.PubMed/NCBI View Article : Google Scholar
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
13	de Boer OJ, van der Wal AC and Becker AE: Atherosclerosis, inflammation, and infection. J Pathol. 190:237–243. 2000.PubMed/NCBI View Article : Google Scholar
14	Libby P, Ridker PM and Hansson GK: Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol. 54:2129–2138. 2009.PubMed/NCBI View Article : Google Scholar
15	Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR and Grunfeld C: IL-1beta mediates leptin induction during inflammation. Am J Physiol. 274:R204–R208. 1998.PubMed/NCBI View Article : Google Scholar
16	Lopez-Castejon G and Brough D: Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 22:189–195. 2011.PubMed/NCBI View Article : Google Scholar
17	Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, Michelson K, Hunter JJ and Kantak SS: Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis. 216:313–320. 2011.PubMed/NCBI View Article : Google Scholar
18	Rus HG, Vlaicu R and Niculescu F: Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 127:263–271. 1996.PubMed/NCBI View Article : Google Scholar
19	Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R and Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int. Suppl:103–108. 2002.PubMed/NCBI View Article : Google Scholar
20	Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S and Shimada K: Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 6:87–91. 1994.PubMed/NCBI View Article : Google Scholar
21	Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, Bond MG, de Faire U, Nilsson J, Eriksson P and Hamsten A: Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 23:376–383. 2002.PubMed/NCBI View Article : Google Scholar
22	Suarez EC, Lewis JG and Kuhn C: The relation of aggression, hostility, and anger to lipopolysaccharide-stimulated tumor necrosis factor (TNF)-alpha by blood monocytes from normal men. Brain Behav Immun. 16:675–684. 2002.PubMed/NCBI View Article : Google Scholar
23	Zhou J, Ma W, Wang X, Liu H, Miao Y, Wang J, Du P, Chen Y, Zhang Y and Liu Z: Matrine suppresses reactive oxygen species (ROS)-mediated MKKs/p38-induced inflammation in oxidized low-density lipoprotein (ox-LDL)-stimulated macrophages. Med Sci Monit. 25:4130–4136. 2019.PubMed/NCBI View Article : Google Scholar
24	Zhong W, Peng J, He H, Wu D, Han Z, Bi X and Dai Q: Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med. 31:E8–E15. 2008.PubMed/NCBI View Article : Google Scholar
25	Kayaselçuk F, Zorludemir S, Gümürdühü D, Zeren H and Erman T: PCNA and Ki-67 in central nervous system tumors: Correlation with the histological type and grade. J Neurooncol. 57:115–121. 2002.PubMed/NCBI View Article : Google Scholar
26	Reed JC: Proapoptotic multidomain Bcl-2/Bax-family proteins: Mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 13:1378–1386. 2006.PubMed/NCBI View Article : Google Scholar
27	Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, Liu BZ and He YJ: Effects of matrine on proliferation and differentiation in K-562 cells. Leuk Res. 25:793–800. 2001.PubMed/NCBI View Article : Google Scholar
28	Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 1(a001651)2009.PubMed/NCBI View Article : Google Scholar
29	Moynagh PN: The NF-kappaB pathway. J Cell Sci. 118:4589–4592. 2005.PubMed/NCBI View Article : Google Scholar
30	Liu J, Zhang L, Ren Y, Gao Y, Kang L and Lu S: Matrine inhibits the expression of adhesion molecules in activated vascular smooth muscle cells. Mol Med Rep. 13:2313–2319. 2016.PubMed/NCBI View Article : Google Scholar